Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation-Reference-Cited by-同舟云学术

Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation

Published:2004-06-21 Issue:1 Volume:66 Page:144-152
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Blount Mitsi A.,Beasley Alfreda,Zoraghi Roya,Sekhar Konjeti R.,Bessay Emmanuel P.,Francis Sharron H.,Corbin Jackie D.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference41 articles.

1. The GAF domain: an evolutionary link between diverse phototransducing proteins

2. EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES

3. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

4. [3H]Sildenafil Binding to Phosphodiesterase-5 Is Specific, Kinetically Heterogeneous, and Stimulated by cGMP

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions;Expert Opinion on Investigational Drugs;2024-08-11

2. Sildenafil Reverses the Neuropathological Alzheimer’s Disease Phenotype in Cholinergic-Like Neurons Carrying the Presenilin 1 E280A Mutation;Journal of Alzheimer's Disease;2024-05-14

3. Development and evaluation of sildenafil/glycyrrhizin-loaded nanofibers as a potential novel buccal delivery system for erectile dysfunction;Saudi Pharmaceutical Journal;2024-05

4. Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism;The Aging Male;2023-12-26

5. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension;Expert Opinion on Investigational Drugs;2023-10-30